High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides

Journal of Biomolecular Screening

Volumn 12, Issue 6, 2007, Pages 775-788

  Low, Jonathan ^a   Shuguang Huang, ^a   Dowless, Michele ^a   Blosser, Wayne ^a   Vincent, Thomas ^b   Davis, Scott ^b   Hodson, Jeff ^b   Koller, Erich ^b   Marcusson, Eric ^b   Blanchard, Kerry ^a   Stancato, Louis ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotide; Distribution analysis; High content screening; Mitosis; siRNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOUBLE STRANDED RNA; OLIGONUCLEOTIDE; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE LIBRARY; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; IMAGING; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TECHNOLOGY; VALIDATION PROCESS;

GENE EXPRESSION PROFILING; HELA CELLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; ORGANISMS, GENETICALLY MODIFIED; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 34548341766     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107302675     Document Type: Article

References (25)

1. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 1978 ; 75 (1). 280-284.
2. Jansen B., Wacheck V., Heere-Ress E., Schlagbauer-Wadl H., Hoeller C., Lucas T.,, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000 ; 356 (9243). 1728-1733.
3. Gewirtz AM: Oligonucleotide therapeutics: a step forward. J Clin Oncol 2000 ; 18 (9). 1809-1811.
4. Monia BP, Lesnik EA, Gonzalez C., Lima WF, McGee D., Guinosso CJ,, et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993 ; 268 (19). 14514-14522.
5. Braasch DA, Corey DR: Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 2002 ; 41 (14). 4503-4510.
6. Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N.,, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003 ; 21 (1). 85-97.
7. Adjei AA, Dy GK, Erlichman C., Reid JM, Sloan JA, Pitot HC,, et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003 ; 9 (1). 115-123.
8. Bartholomeusz C., Itamochi H., Yuan LX, Esteva FJ, Wood CG, Terakawa N.,, et al. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res 2005 ; 65 (18). 8406-8413.
9. Marshall JL, Eisenberg SG, Johnson MD, Hanfelt J., Dorr FA, El-Ashry D.,, et al. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2004 ; 4 (4). 268-274.
10. Chi KN, Eisenhauer E., Fazli L., Jones EC, Goldenberg SL, Powers, J. et al: A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005 ; 97 (17). 1287-1296.
11. Fire A., Xu S., Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998 ; 391 (6669). 806-811.
12. Bernstein E., Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001 ; 409 (6818). 363-366.
13. Hammond SM, Bernstein E., Beach D., Hannon GJ: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000 ; 404 (6775). 293-296.
14. Spee B., Jonkers MD, Arends B., Rutteman GR, Rothuizen J., Penning LC: Specific down-regulation of XIAP with RNA interference enhances the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin. Mol Cancer 2006 ; 5: 34.
15. Nozawa H., Tadakuma T., Ono T., Sato M., Hiroi S., Masumoto K.,, et al. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 2006 ; 97 (10). 1115-1124.
16. Barik S., Bitko V.: Prospects of RNA interference therapy in respiratory viral diseases: update 2006. Expert Opin Biol Ther 2006 ; 6 (11). 1151-1160.
17. Shen J., Samul R., Silva RL, Akiyama H., Liu H., Saishin Y.,, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2005 ; 13 (3). 225-234.
18. Giuliano KA, Haskins JR, Taylor DL: Advances in high content screening for drug discovery. Assay Drug Dev Technol 2003 ; 1 (4). 565-577.
19. Bennett CF, Cowsert LM Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim Biophys Acta 1999 ; 1489 (1). 19-30.
20. Silverman BW Density Estimation for Statistics and Data Analysis. London: Chapman & Hall/CRC, 1986.
21. Venables WN, Ripley BD: Modern Applied Statistics with S. New York: Springer, 2002.
22. Ghosh RN, Grove L., Lapets O.: A quantitative cell-based high-content screening assay for the epidermal growth factor receptor-specific activation of mitogen-activated protein kinase. Assay Drug Dev Technol 2004 ; 2 (5). 473-481.
23. Montgomery DC: Design and Analysis of Experiments. New York: John Wiley & Sons, 1997.
24. Bilanges B., Stokoe D.: Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem J 2005 ; 388 (pt2). 573-583.
25. Holmlund JT Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development. Ann N Y Acad Sci 2003 ; 1002: 244-251.